Immediate Impact
57 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
2025 Standout
Works of Yanrong Hao being referenced
Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
2022
The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation.
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Yanrong Hao | 89 | 119 | 40 | 43 | 32 | 271 | |
| Xianglei Wu | 106 | 87 | 61 | 58 | 25 | 331 | |
| Guofei Feng | 56 | 117 | 73 | 62 | 27 | 307 | |
| Siqi Ren | 82 | 114 | 48 | 34 | 34 | 286 | |
| Yuan Peng | 78 | 133 | 25 | 64 | 30 | 290 | |
| Mohammed A. Hannan | 53 | 142 | 84 | 17 | 30 | 320 | |
| Yuqian Feng | 69 | 99 | 39 | 59 | 24 | 319 | |
| Jo‐Ting Tsai | 86 | 68 | 24 | 94 | 30 | 289 | |
| Guanglu Dong | 53 | 158 | 63 | 45 | 22 | 288 | |
| Flavia Bruna | 37 | 81 | 43 | 36 | 28 | 257 | |
| Quan Liu | 60 | 80 | 21 | 23 | 44 | 236 |
All Works
Login with ORCID to disown or claim papers
Loading papers...